Studies using transgenic mice have also shown that pharmacological stimulation of HO-1 activity may ameliorate ischemic injury during the acute period of stroke [13], and pharmaceutical induction of HO-1 by the HO-1 activator CoPP ameliorated retinal damage due to I/R injury [14], [47], [48]. The gene discussed is HMOX1; the disease is Stroke.